Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.

European journal of haematology - 1 Jul 2015

Jonasova Anna, Bokorova Radka, Polak Jaroslav, Vostry Martin, Kostecka Arnost, Hajkova Hana, Neuwirtova Radana, Siskova Magda, Sponerova Dana, Cermak Jaroslav, Mikulenkova Dana, Cervinek Libor, Brezinova Jana, Michalova Kyra, Fuchs Ota

Abstract excerpt

Downregulation of cereblon (CRBN) gene expression is associated with resistance to the immunomodulatory drug lenalidomide and poor survival outcomes in multiple myeloma (MM) patients. However, the importance of CRBN gene expression in patients with myelodysplastic syndrome (MDS) and its impact on lenalidomide therapy are not clear. In this study, we evaluate cereblon expression in mononuclear cells isolated from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromosomes, Human, Pair 5
Share to Immunologic Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lenalidomide

Share to Leukocytes, Mononuclear

Share to Myelodysplastic Syndromes

Share to Peptide Hydrolases

Share to RNA Splicing

Share to Thalidomide

Source

Identifiers

PMID: 25284710
DOI: 10.1111/ejh.12457

Genes

CRBN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.PMID 25284710Read ↗

Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma.Semantic proximity Read ↗

Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5qSemantic proximity Read ↗

Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome.Semantic proximity Read ↗

A precision medicine approach to the myelodysplastic syndrome with isolated deletion 5q, 50 years after its discoverySemantic proximity Read ↗

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myelomaSemantic proximity Read ↗

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomideSemantic proximity Read ↗

Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapySemantic proximity Read ↗

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.Semantic proximity Read ↗

Cereblon expression in multiple myeloma: not ready for prime timeSemantic proximity Read ↗

Detection and Quantification of Cereblon Protein and mRNA in Multiple Myeloma Cell Lines and Primary CD138+multiple Myeloma CellsSemantic proximity Read ↗

Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patientsSemantic proximity Read ↗

Biological and Prognostic Significance of Chromosome 5q Deletions in Myeloid MalignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.